Trial Title:
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
NCT ID:
NCT05866692
Condition:
Solid Tumor, Adult
Conditions: Official terms:
Neoplasms
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
TY-2699a
Description:
TY-2699a PO, BID
Escalation stage: increased dose cohorts from low dose to MTD
Expansion stage: The dose for the Expansion stage will be determined based on results
Arm group label:
TY-2699a
Summary:
This is a phase I, multicenter, open-label study. The study will investigate the safety,
tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic
solid tumors.
Detailed description:
To assess the safety and tolerability of TY-2699a when administered as a single agent in
subjects with locally advanced or metastatic solid tumors.
To determine the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) as
a single agent in subjects with locally advanced or metastatic solid tumors.
To evaluate the pharmacokinetics (PK) of TY-2699a administered at single and multiple
oral doses.
To assess the preliminary antitumor activity of TY-2699a as a single agent in subjects
with locally advanced or metastatic solid tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Be able to provide written informed consent approved by institutional review board
(IRB) or independent ethics committee (IEC).
2. Age ≥18 years.
3. At the escalation stage, patients should fulfill the following criteria at
Screening:
1) Participants with locally advanced or metastatic solid tumors including TNBC,
ER+HER2-BC, ovarian cancer, small cell lung cancer, castrate-resistant prostate
cancer (CRPC), or PDAC with KRAS mutant; Or any other locally advanced or metastatic
solid tumor with evidence of deregulated RB-pathway based on available molecular
test results and after sponsor review to confirm eligibility as determined with
prior molecular assays performed in a CLIA-certified or equivalent laboratory.
(Note: ① 0% - 1% of tumor cells expressing ER or PR as negative while ≥ 1% of tumor
cells expressing ER or PR as positive on IHC staining, recommended by ASCO/CAP
guideline Update 2020; negative HER2 is defined as IHC 0 or 1+, or IHC 2+ but
confirmed by the negative ISH, recommended by ASCO/CAP Guideline 2018; ② Genes of
KRAS and other biomarkers will be detected by the Polymerase Chain Reaction (PCR) or
Next-Generation Sequencing (NGS)); 2) Patients who have progressed on established
standard medical anti-cancer therapies for a given tumor type or have been
intolerant to such therapy, or in the opinion of the investigator have been
considered ineligible for a particular form of standard therapy on medical grounds.
4. At the expansion stage, patients should fulfill the following criteria at Screening
:
1)Cohort : TNBC patients progressed on ≥ 2 previous lines of therapy and/or other solid
tumors will receive TY-2699a. ① Previous therapy can be of any nature (chemotherapy,
immunotherapy, antiangiogenics, experimental therapy, etc.); ② Histologically-confirmed
breast carcinoma not expressing ER, PR, and HER2 (negative ER and PR is defined as < 1%
tumor cells expressing ER and PR on IHC staining, recommended by ASCO/CAP Guideline
Update 2020; negative HER2 is defined as IHC staining 0 or 1+ , or IHC 2+ but confirmed
by the negative ISH, recommended by ASCO/CAP Guideline 2018; negative HER2 is defined as
IHC 0 or 1+, or IHC 2+ but confirmed by the negative ISH, recommended by ASCO/CAP
Guideline 2018); ③ With or without BRCA mutation.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and life
expectancy > 3 months.
6. Capability to swallow intact capsule (without chewing, crushing or opening). 7. At
least 1 measurable target lesion according to Response Evaluation Criteria in Solid
Tumor Version 1.1 (RECIST v1.1, Appendices 15.2 RECIST v1.1 ) determined by the
investigator.
8. All acute toxic effects (excluding alopecia and neuropathy associated with prior
platinum-based drug therapy) of any prior therapy recovered to grade ≤1 based on NCI
CTCAE v5.0.
9. Baseline laboratory results fulfilling the following requirements: Absolute
neutrophils count (ANC) ≥1500/mm3 (1.5×109/L) * Platelets ≥100,000/mm3 (100×109/L) *
Hemoglobin > 90 g/L* Estimated creatinine clearance ≥55 mL/min+ Total serum
bilirubin <1.5 × ULN <3.0 × ULN if known Gilbert's disease Liver transaminases
(AST/ALT) <2.5 × ULN; <5 × ULN if liver metastases are present ULN: upper limit
normal.
- No blood transfusion, blood products, or hematopoietic factors such as G-CSF,
erythropoietin or albumin within 14 days prior to first dose.
- Cockcroft-Gault Equation. 10. For female patients of childbearing potential,
the serum or urine pregnancy test within 7 days prior to the start of TY-2699a
treatment should be negative.
11. Male and female patients of childbearing potential must agree to use at
least two method of highly effective contraception from signing ICF,
throughout the study and continued for 90 days after the last dose of
TY-2699a treatment at the escalation stage or for the labeled duration of
contraception of the combined approved drug fulvestrant (e.g., FASLODEX
requires one-year contraception after the last dose) or PD-L1 antibody
(will decide a brand approved in US before starting expansion stage) after
the last dose at the expansion stage.
12. Willing and able to comply with all aspects of the protocol.
Exclusion Criteria:
1. Concurrent participation in another interventional clinical trial, unless the
patient at long-term follow-up period.
2. Patients with the following treatment:
1. Received undergone major surgery (except minor surgery such as appendicitis,
tumor biopsy, etc.) within 4 weeks prior to the first dose.
2. Received bone marrow (equal to area of pelvis) or extensive radiation therapy
within 28 days prior to the first dose; received local radiation therapy (e.g.,
thoracic spine and rib radiation therapy) within 7 days prior to the first dose
of the study drug.
3. Received CYP3A and CYP2C8 strong inducers/strong inhibitors or p-gp
glycoprotein inhibitors within 14 days prior to the first dose (see Appendices
15.3 Examples of CYP450-related Drugs/food).
4. History of proton pump inhibitors (PPIs) within 4 days prior to the first dose
of TY-2699a; OR history of histamine H2 blockers within 2 days prior to the
first dose of TY-2699a. Patients who are receiving and require continuation of
drug therapy during the study with drugs known to prolong the QTc interval or
that may cause torsades de pointes.
5. Prior exposure to transcriptional kinase family CDK inhibitors, such as the
CDK7 and CDK9 inhibitors SY-5609，CT-7001，Alvocidib，Dinaciclib，Seliciclib and
SY-1365. Exception: Previous exposure to cell cycle CDK inhibitors such as
inhibitors of CDK4 and CDK6 (ie, palbociclib) is allowed.
3. History of other previous cancer (except for squamous cell or basal-cell carcinoma
of the skin, or any in situ carcinoma that has been completely resected), requiring
therapy within the previous 5 years
4. Patients with unstable brain metastases: Patients with CNS complications requiring
urgent neurosurgical treatment (e.g., surgery, etc.) (except when surgery is
completed >7 days and side effects from complications are ≤ grade 1); patients
requiring glucocorticoids, mannitol or diuretics at equivalent doses greater than 4
mg of dexamethasone to control symptoms of brain metastases within 14 days prior to
the first study dose; patients who have undergone whole brain radiation therapy or
gamma knife within 14 days prior to the first study dose; patients with symptoms of
spinal cord compression from the tumor. Note: conversely, patients with stable CNS
metastasis and those who are beyond the treatment washout period of 14 days per
protocol are eligible to the study.
5. Epilepsy needing treatment; having a history of psychotropic substance abuse that
cannot abstain; have mental disorders (successful abstain must pass at least 2 weeks
without observing withdrawal reaction).
6. Patients receiving long-term systemic immunosuppressant therapy (≤10 mg/ day of
prednisone or other equivalent dose of corticosteroid inhalation or topical
administration can be included).
7. Any of the following cardiac criteria:
1. Mean resting corrected QT interval (electrocardiogram interval measured from
the onset of the QRS complex to the end of the T wave) for heart rate QTc > 470
msec obtained from 3 electrocardiograms, using the screening clinic
electrocardiogram machine derived QTc value.
2. Any clinically important abnormalities in rhythm, conduction, or morphology of
resting electrocardiogram (e.g., complete left bundle branch block,
third-degree heart block, second-degree heart block, PR interval >250 msec).
Any factors that increase the risk of QTc prolongation or risk of arrhythmic
events such as heart failure, hypokalemia, congenital long QT syndrome, family
history of long QT syndrome, or any concomitant medication known to prolong the
QT interval during Screening.
3. Left ventricular ejection fraction (LVEF) <50%；
4. Clinically significant cardiovascular disease (either active at Screening or
within 6 months prior to enrollment): myocardial infarction, unstable angina,
coronary/peripheral artery bypass graft, symptomatic congestive heart failure
(New York Heart Association Classification Class ≥II), cerebrovascular accident
or transient ischemic attack, stroke, symptomatic bradycardia, or requirement
for anti-arrhythmic medication.
5. Unstable patients that may affect their safety or compliance of study, any
serious or uncontrolled systemic disease including uncontrolled high blood
pressure (systolic blood pressure >160mmHg, or diastolic pressure >100mmHg),
uncontrolled diabetes (fasting plasma glucose >10 mmol/L), active bleeding,
severe eye disease, severe psychosis, nerve, vascular, or respiratory disease.
8. Known active infections, including human immunodeficiency virus (HIV), hepatitis B
virus (HBV), and hepatitis C virus (HCV) infection, except for asymptomatic chronic
HBV or HCV carriers. Active HBV, HCV, or HIV infections are defined as
1. Hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥ 2000 cps/mL or 500
IU/mL; HBsAg-negative, anti-HBc-positive patients are at high risk of HBV
reactivation who require suppressive antiviral therapy prior to initiation of
cancer therapy
2. Anti-HCV antibody positive and HCV-RNA > upper normal limit defined by sites
3. Anti-HIV antibody positive with uncontrolled opportunistic infections; anti-HIV
antibody positive with CD4+ count < 350 cells/uL that requires HIV therapy
prior to the cancer treatment; other conditions allowing concurrent ART but the
therapy not tolerated and that the toxicities confused with investigational
drug toxicities. Note: Examples of drug-drug interactions that affect
absorption, distribution, metabolism, and excretion of the TY-2699a are shown
in Appendices 15.3 Examples of CYP450-related Drugs/food.
9. Diagnosed interstitial lung disease with or without symptoms, as well as conditions
that may cause pulmonary toxicity or related pneumonia after using TY-2699a, or
pulmonary symptoms deemed by the investigator to have high risk of developing
interstitial lung disease. Note: Patients with history of prior radiation
pneumonitis will not be excluded.
10. Active gastrointestinal disease with significant symptoms (e.g., gastric ulcer,
Crohn's disease, ulcerative colitis, short gut syndrome) or other malabsorption
syndromes that will impact in ingesting, transporting, or absorbing the drug.
11. Known/suspected allergy to the composition of TY-2699a or the analogues.
12. Pregnant and breastfeeding women.
13. The Prinicpal Investigator considers that the patient is not suitable to participate
in this study.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Address:
City:
Beijing
Zip:
100021
Country:
China
Status:
Recruiting
Contact:
Last name:
Xu Binghe, MD
Phone:
8610-87788495
Email:
cancergep@163.com
Investigator:
Last name:
Xu Binghe, MD
Email:
Principal Investigator
Investigator:
Last name:
Zhang Pin, MD
Email:
Sub-Investigator
Facility:
Name:
Shandong Cancer Hospital
Address:
City:
Jinan
Zip:
250117
Country:
China
Status:
Recruiting
Contact:
Last name:
Sun Yuping
Phone:
0531-67626929
Email:
13370582181@163.com
Investigator:
Last name:
Sun Yuping
Email:
Principal Investigator
Investigator:
Last name:
Li Huihui
Email:
Principal Investigator
Start date:
August 17, 2023
Completion date:
October 2026
Lead sponsor:
Agency:
TYK Medicines, Inc
Agency class:
Industry
Source:
TYK Medicines, Inc
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05866692
